研究者業績

大澤 英之

オオザワ ヒデユキ  (Hideyuki Ohzawa)

基本情報

所属
自治医科大学 附属病院腫瘍センター臨床腫瘍部 准教授

J-GLOBAL ID
201901012051989248
researchmap会員ID
B000348091

論文

 154
  • Hideyuki Ohzawa, Atsushi Miki, Yasuo Hozumi, Chieko Miyazaki, Yuka Sagara, Yumiko Tanaka, Satomi Shiba, Hiromi Joutoku, Masako Sakuragi, Megumi Takehara, Yasunaru Sakuma, Wataru Nishimura, Hirofumi Fujii, Yoshikazu Yasuda
    ONCOLOGY LETTERS 9(1) 119-124 2015年1月  査読有り
    Chemotherapy-induced nausea and vomiting is a serious adverse side-effect of anthracycline-based chemotherapy regimens, in patients with breast cancer. A combination of three drugs, 5-hydroxytryptamine (5-HT3) receptor antagonist, aprepitant and dexamethasone, is recommended for antiemetic therapy. Palonosetron (PALO), a novel 5-HT3 receptor antagonist has been identified to be effective against delayed nausea and vomiting. In this study, the results of PALO for patients who received anthracycline-based chemotherapy were compared with that of granisetron (GRA) using a crossover study design. This study evaluated the efficacy of antiemetics in the first cycle of chemotherapy, as well as the second and third cycles. A total of 21 patients and 19 patients were assigned to PALO and GRA treatment groups during the first cycle of chemotherapy, respectively. The patients switched to the other antiemetic drug for the second chemotherapy cycle (PALO followed by GRA or GRA followed by PALO). The patients could select PALO or GRA antiemetics for the third cycle, according to their preference. A total of 21 patients selected PALO and 18 patients selected GRA in the third cycle, and one patient was withdrawn from the study as their third cycle questionnaire was not obtained. No significant differences between PALO and GRA were identified in first and second cycles. However, during the third cycle, a significant difference was observed in acute-phase complete control of emetic events between the PALO and GRA groups, which was defined as no emetic episode, no additional antiemetic treatment and no more than mild nausea, between PALO and GRA. These results demonstrated that changing antiemetics may affect the efficacy of antiemetics. This study indicates that alteration of antiemetic regimens, including drug combination and order, may improve the efficacy of antiemetic treatment.
  • Hideyuki Ohzawa, Takashi Sakatani, Toshiro Niki, Yoshikazu Yasuda, Yasuo Hozumi
    BREAST CANCER 21(5) 563-570 2014年9月  査読有り
    The effectiveness of neoadjuvant chemotherapy is evaluated on the basis of pathological responses and survival outcome, because achievement of a pathological complete response (pCR) is a good predictor of long-term survival. However, few studies have assessed the survival of breast cancer patients who received neoadjuvant chemotherapy including trastuzumab. The records of 161 breast cancer patients who received neoadjuvant chemotherapy between January 2006 and December 2011 were retrospectively reviewed. The patients were categorized into 4 subgroups on the basis of the status of the estrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). HER2-positive patients received trastuzumab-based regimens. Pathological responses and survival were analyzed on the basis of breast cancer subtypes. The pCR results obtained were: luminal A and B (ER and/or PR-positive, HER2-negative), 6.3 % (5/79 cases); luminal-HER2 hybrid (ER and/or PR-positive, HER2-positive), 25.0 % (5/20 cases); HER2-enriched (ER and PR-negative, HER2-positive), 63.0 % (17/27 cases); and triple-negative (ER and PR-negative, HER2-negative), 25.7 % (9/35 cases). Achievement of pCR was a good predictor of disease-free survival in the HER2-enriched group. Overall survival of patients with pCR was slightly, but not significantly, better in the HER2-enriched and triple-negative subgroups. Responses and survival after neoadjuvant chemotherapy including trastuzumab of patients with HER2-positive tumors differed among disease subtypes. Our findings suggest that disease subtype is an important determinant of the efficacy of neoadjuvant chemotherapy.
  • 桂木 容子, 宇田 宏一, 菅原 康志, 穂積 康夫, 竹原 めぐみ, 塩澤 幹雄, 櫻木 雅子, 宮崎 千絵子, 大沢 英之, 尾本 和
    日本乳癌学会総会プログラム抄録集 21回 427-427 2013年6月  
  • 本多 寛之, 大澤 英之, 金丸 理人, 宮崎 千絵子, 尾本 和, 竹原 めぐみ, 坂谷 貴司, 穂積 康夫
    日本臨床外科学会雑誌 72(12) 3214-3214 2011年12月  

MISC

 30

講演・口頭発表等

 98

共同研究・競争的資金等の研究課題

 8